Orris
attachment
attachment

Answer

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Here are model answers for all 12 reasoning questions (3 marks each), grounded in standard pharmacology texts.

1 & 11. Why Atropine is contraindicated in narrow-angle/angle-closure glaucoma

Atropine is a non-selective muscarinic antagonist. By blocking M3 receptors on the iris sphincter and ciliary muscle, it causes mydriasis (pupillary dilation) and cycloplegia. In a normal (open) anterior chamber angle this is harmless, but in a person with a pre-existing narrow/shallow anterior chamber angle, pupillary dilation pushes the thickened peripheral iris root further into the angle, mechanically blocking the trabecular meshwork/canal of Schlemm and obstructing aqueous humor outflow. This causes a sharp, dangerous rise in intraocular pressure - precipitating an acute angle-closure glaucoma attack, which can cause irreversible optic nerve damage within hours. Atropine has no effect on IOP in a normal open angle, which is why it is specifically the angle-closure/narrow-angle subtype that is at risk - Lippincott Illustrated Reviews Pharmacology; Barash, Cullen and Stoelting's Clinical Anesthesia, 9e.

2. Propranolol (not atenolol) for tremor

Essential/physiologic tremor is mediated mainly through peripheral beta-2 adrenergic receptors in skeletal muscle spindles. Propranolol is a non-selective (beta-1 + beta-2) blocker, so it blocks the beta-2-mediated enhancement of muscle spindle sensitivity and reduces tremor amplitude effectively. Atenolol is a beta-1 selective (cardioselective) blocker with little beta-2 blocking activity, so it is far less effective against tremor. Studies confirm tremor responds best to agents with beta-2 activity, which is why propranolol (or metoprolol at higher doses) is preferred over atenolol - Katzung's Basic and Clinical Pharmacology, 16th ed; Adams and Victor's Principles of Neurology.

3. Why clonidine is not stopped abruptly

Clonidine is a central alpha-2 adrenergic agonist that chronically suppresses sympathetic outflow from the vasomotor centre, leading to compensatory upregulation/supersensitivity of alpha and beta adrenoceptors and a build-up of stored catecholamines. If the drug is withdrawn suddenly, this suppression is lost abruptly while the receptor supersensitivity persists, causing a rebound sympathetic surge - severe rebound hypertension (sometimes exceeding baseline), tachycardia, anxiety, tremor, and sweating, occurring typically 18-36 hours after the last dose. This is why clonidine must always be tapered gradually over 1-2 weeks - The Washington Manual of Medical Therapeutics.

4. Why physostigmine is preferred in atropine poisoning

Atropine poisoning causes a central and peripheral anticholinergic toxidrome (delirium, hallucinations, hyperthermia, tachycardia, mydriasis, dry flushed skin). Physostigmine is a tertiary amine, lipid-soluble cholinesterase inhibitor that readily crosses the blood-brain barrier, allowing it to reverse both the central and peripheral antimuscarinic effects of atropine by increasing synaptic acetylcholine to out-compete atropine at muscarinic receptors. Other cholinesterase inhibitors like neostigmine are quaternary amines that cannot cross the BBB and so only reverse peripheral effects, leaving the dangerous CNS delirium untreated. This is why physostigmine is the specific antidote of choice for anticholinergic (atropine) poisoning - Lippincott Illustrated Reviews Pharmacology; Morgan and Mikhail's Clinical Anesthesiology.
(Note: Because physostigmine itself can cause bradycardia, seizures, and cholinergic crisis, current toxicology practice reserves it for severe, refractory anticholinergic delirium rather than routine use - Katzung's Pharmacology.)

5. Alpha blockers and finasteride in BPH treatment

These two drug classes act on the two components that cause bladder outlet obstruction in BPH:
  • Alpha-1 blockers (e.g., prazosin, terazosin, tamsulosin, silodosin) block alpha-1 adrenoceptors in the smooth muscle of the prostate capsule, bladder neck and urethra, relaxing this smooth muscle and relieving the dynamic/functional component of obstruction. Their effect is rapid (days).
  • Finasteride (a 5-alpha-reductase inhibitor) blocks conversion of testosterone to dihydrotestosterone (DHT), the main androgen driving prostatic glandular growth. This shrinks the gland over months, reducing the static/mechanical component of obstruction.
Because they act by different, complementary mechanisms (functional vs structural), the two are often combined for better symptom relief, especially in men with larger prostates.

6. Why Adrenaline is given in anaphylactic shock

Anaphylaxis is a massive IgE-mediated mast cell/basophil degranulation releasing histamine and other mediators causing systemic vasodilation, capillary leak (hypotension/shock), bronchospasm, and laryngeal edema. Adrenaline (epinephrine) is the drug of choice because it acts on all the relevant receptors simultaneously:
  • Alpha-1: vasoconstriction, reversing hypotension and reducing mucosal/laryngeal edema
  • Beta-1: increases heart rate and contractility, supporting cardiac output
  • Beta-2: bronchodilation, relieving bronchospasm, and it also stabilizes mast cells, reducing further mediator release
No other drug reverses all three life-threatening components (hypotension, bronchospasm, edema) as rapidly, which is why IM adrenaline is first-line, given immediately without waiting for other therapy - Dermatology 2-Volume Set, 5e; Essentials of Forensic Medicine and Toxicology.

7. Why atropine is ineffective in organophosphate-induced muscle paralysis

Organophosphates irreversibly inhibit acetylcholinesterase, causing accumulation of acetylcholine at both muscarinic and nicotinic synapses. Atropine is a pure muscarinic antagonist - it effectively reverses the muscarinic effects (salivation, bronchorrhea, bradycardia, miosis) but has no activity at nicotinic receptors. Skeletal muscle weakness/paralysis (fasciculations progressing to flaccid paralysis, and respiratory muscle failure) is mediated through nicotinic receptors at the neuromuscular junction, which atropine cannot block. Hence atropine treats the muscarinic (secretory/cardiovascular) crisis but does not touch the neuromuscular paralysis - this requires pralidoxime (2-PAM), which reactivates acetylcholinesterase itself - Tintinalli's Emergency Medicine; Rosen's Emergency Medicine.

8. Silodosin in BPH

Silodosin is a highly uroselective alpha-1A adrenoceptor antagonist. The alpha-1A subtype predominates in prostatic smooth muscle and bladder neck, whereas alpha-1B is mainly vascular. Because silodosin has much greater selectivity for alpha-1A over alpha-1B compared to older non-selective alpha blockers, it relaxes prostatic/bladder neck smooth muscle and relieves obstructive voiding symptoms in BPH with a markedly lower incidence of orthostatic hypotension. Its main characteristic side effect is retrograde/abnormal ejaculation, due to this same uroselectivity affecting seminal vesicle and vas deferens smooth muscle.

9. Why propranolol is contraindicated in asthmatic patients

Bronchodilation is normally maintained by tonic sympathetic activity acting on beta-2 receptors in bronchial smooth muscle. Propranolol is a non-selective beta-blocker, blocking both beta-1 and beta-2 receptors. By blocking bronchial beta-2 receptors, it removes bronchodilator tone and can precipitate severe, potentially fatal bronchospasm in asthmatics; it can also blunt the rescue effect of endogenous or administered epinephrine/beta-2 agonists during an attack. Cardioselective beta-1 blockers (e.g., metoprolol) are comparatively safer, but even they should be used cautiously - Lippincott Illustrated Reviews Pharmacology.

10. Why prazosin causes the "first-dose phenomenon"

Prazosin selectively blocks post-synaptic alpha-1 receptors, causing venous and arteriolar dilation. With the very first dose (especially if large), this sudden fall in peripheral resistance and venous return occurs before compensatory reflex mechanisms (baroreceptor-mediated tachycardia/fluid retention) have adjusted, producing a marked, acute drop in blood pressure - manifesting as postural hypotension, dizziness, and syncope, typically 30-90 minutes after the first dose (or after a dose increase). Because alpha-2 receptors (which normally provide negative feedback inhibition of norepinephrine release) are spared, this doesn't fully compensate for the abrupt alpha-1 blockade. This is why prazosin therapy is started with a small test dose at bedtime and titrated slowly upward - Goodman & Gilman's The Pharmacological Basis of Therapeutics.

12. Why neostigmine is preferred over physostigmine for myasthenia gravis

Myasthenia gravis is a peripheral neuromuscular junction disorder (autoantibodies against nicotinic ACh receptors at skeletal muscle), so treatment only needs to boost peripheral acetylcholine levels at the NMJ. Neostigmine is a quaternary amine cholinesterase inhibitor - it is poorly lipid-soluble and does not cross the blood-brain barrier, so it increases acetylcholine at the neuromuscular junction (improving muscle strength) without producing central cholinergic side effects (confusion, seizures). Physostigmine, being a tertiary amine, readily crosses the BBB and causes unwanted CNS cholinergic toxicity (agitation, seizures) at doses needed for peripheral effect, and also has a shorter duration of action - making it unsuitable and unnecessary for a purely peripheral disease like myasthenia gravis - Lippincott Illustrated Reviews Pharmacology; Ganong's Review of Medical Physiology.
These are classic mechanism-based pharmacology viva/theory answers (autonomic and CNS pharmacology) - a quick recent-evidence check via PubMed wasn't necessary here since these are stable, foundational pharmacologic mechanisms rather than evolving clinical-trial topics. Let me know if you'd like any of these expanded into a longer answer with diagrams for exam writing.
attachment
attachment

Answer

This is a large set (37 questions, many duplicates) covering antimicrobial and chemotherapy pharmacology rationale questions. Rather than dump 37 short answers at once, here's the topic map - duplicates across colleges collapse into ~20 distinct concepts:
Unique topics covered:
  1. Piperacillin-tazobactam (beta-lactamase inhibitor combination)
  2. Folinic acid (leucovorin) "rescue" with methotrexate - and why folinic, not folic, acid (appears 8x: Q2,5,9,14,19,23,28,32)
  3. Metronidazole + alcohol (disulfiram-like reaction) (Q3, Q34)
  4. Cilastatin + Imipenem (Q4, Q15)
  5. Ethambutol caution/avoidance in young children (Q6, Q30)
  6. MESNA with cyclophosphamide (hemorrhagic cystitis prevention)
  7. Aminoglycoside therapeutic drug monitoring + why ineffective orally (Q8, Q31)
  8. Rifampicin causing oral contraceptive failure
  9. Amphotericin B cautious/slow infusion
  10. Primaquine and G6PD deficiency + single-dose use in P. falciparum (Q12, Q25)
  11. Rationale of combined/synergistic antimicrobial therapy (general principle)
  12. Latest BPaL/BPaLM regimen for MDR-TB
  13. Amoxicillin + clavulanic acid (Q17, Q22, Q35)
  14. Cotrimoxazole synergism - sulfamethoxazole + trimethoprim (Q18, Q36, Q37)
  15. Antibiotics contraindicated in pregnancy (naming two + reasons)
  16. Tetracycline avoided in children and pregnancy
  17. Metronidazole in pseudomembranous (C. difficile) enterocolitis
  18. Pyridoxine combined with anti-TB regimen (isoniazid-induced neuropathy)
  19. Penicillin + probenecid co-administration rationale
  20. Sulfonamides less effective in presence of pus
  21. Beta-lactams ineffective against Mycoplasma
Brief overview: Most of these questions test the same handful of pharmacology principles repeated across drug pairs: (a) protecting a beta-lactam from bacterial enzymatic destruction (tazobactam, clavulanate, cilastatin), (b) rescuing normal cells from a cytotoxic drug's off-target effect (folinic acid/methotrexate, MESNA/cyclophosphamide, pyridoxine/isoniazid), (c) synergistic sequential blockade of the same pathway (cotrimoxazole), (d) genetic/enzyme-deficiency-based toxicity (primaquine/G6PD), and (e) pharmacokinetic interactions altering drug levels (rifampicin enzyme induction, probenecid blocking renal secretion, aminoglycoside narrow therapeutic index needing TDM).
Which topic would you like me to answer in full detail first (with mechanism, textbook citations, and exam-ready 3/5-mark structure)?
Asking for Preferences

Which topic(s) should I answer in detail first?

Here are model answers for all 12 reasoning questions (3 marks each), grounded in standard pharmacology texts.

1 & 11. Why Atropine is contraindicated in narrow-angle/angle-closure glaucoma

Atropine is a non-selective muscarinic antagonist. By blocking M3 receptors on the iris sphincter and ciliary muscle, it causes mydriasis (pupillary dilation) and cycloplegia. In a normal (open) anterior chamber angle this is harmless, but in a person with a pre-existing narrow/shallow anterior chamber angle, pupillary dilation pushes the thickened peripheral iris root further into the angle, mechanically blocking the trabecular meshwork/canal of Schlemm and obstructing aqueous humor outflow. This causes a sharp, dangerous rise in intraocular pressure - precipitating an acute angle-closure glaucoma attack, which can cause irreversible optic nerve damage within hours. Atropine has no effect on IOP in a normal open angle, which is why it is specifically the angle-closure/narrow-angle subtype that is at risk - Lippincott Illustrated Reviews Pharmacology; Barash, Cullen and Stoelting's Clinical Anesthesia, 9e.

2. Propranolol (not atenolol) for tremor

Essential/physiologic tremor is mediated mainly through peripheral beta-2 adrenergic receptors in skeletal muscle spindles. Propranolol is a non-selective (beta-1 + beta-2) blocker, so it blocks the beta-2-mediated enhancement of muscle spindle sensitivity and reduces tremor amplitude effectively. Atenolol is a beta-1 selective (cardioselective) blocker with little beta-2 blocking activity, so it is far less effective against tremor. Studies confirm tremor responds best to agents with beta-2 activity, which is why propranolol (or metoprolol at higher doses) is preferred over atenolol - Katzung's Basic and Clinical Pharmacology, 16th ed; Adams and Victor's Principles of Neurology.

3. Why clonidine is not stopped abruptly

Clonidine is a central alpha-2 adrenergic agonist that chronically suppresses sympathetic outflow from the vasomotor centre, leading to compensatory upregulation/supersensitivity of alpha and beta adrenoceptors and a build-up of stored catecholamines. If the drug is withdrawn suddenly, this suppression is lost abruptly while the receptor supersensitivity persists, causing a rebound sympathetic surge - severe rebound hypertension (sometimes exceeding baseline), tachycardia, anxiety, tremor, and sweating, occurring typically 18-36 hours after the last dose. This is why clonidine must always be tapered gradually over 1-2 weeks - The Washington Manual of Medical Therapeutics.

4. Why physostigmine is preferred in atropine poisoning

Atropine poisoning causes a central and peripheral anticholinergic toxidrome (delirium, hallucinations, hyperthermia, tachycardia, mydriasis, dry flushed skin). Physostigmine is a tertiary amine, lipid-soluble cholinesterase inhibitor that readily crosses the blood-brain barrier, allowing it to reverse both the central and peripheral antimuscarinic effects of atropine by increasing synaptic acetylcholine to out-compete atropine at muscarinic receptors. Other cholinesterase inhibitors like neostigmine are quaternary amines that cannot cross the BBB and so only reverse peripheral effects, leaving the dangerous CNS delirium untreated. This is why physostigmine is the specific antidote of choice for anticholinergic (atropine) poisoning - Lippincott Illustrated Reviews Pharmacology; Morgan and Mikhail's Clinical Anesthesiology.
(Note: Because physostigmine itself can cause bradycardia, seizures, and cholinergic crisis, current toxicology practice reserves it for severe, refractory anticholinergic delirium rather than routine use - Katzung's Pharmacology.)

5. Alpha blockers and finasteride in BPH treatment

These two drug classes act on the two components that cause bladder outlet obstruction in BPH:
  • Alpha-1 blockers (e.g., prazosin, terazosin, tamsulosin, silodosin) block alpha-1 adrenoceptors in the smooth muscle of the prostate capsule, bladder neck and urethra, relaxing this smooth muscle and relieving the dynamic/functional component of obstruction. Their effect is rapid (days).
  • Finasteride (a 5-alpha-reductase inhibitor) blocks conversion of testosterone to dihydrotestosterone (DHT), the main androgen driving prostatic glandular growth. This shrinks the gland over months, reducing the static/mechanical component of obstruction.
Because they act by different, complementary mechanisms (functional vs structural), the two are often combined for better symptom relief, especially in men with larger prostates.

6. Why Adrenaline is given in anaphylactic shock

Anaphylaxis is a massive IgE-mediated mast cell/basophil degranulation releasing histamine and other mediators causing systemic vasodilation, capillary leak (hypotension/shock), bronchospasm, and laryngeal edema. Adrenaline (epinephrine) is the drug of choice because it acts on all the relevant receptors simultaneously:
  • Alpha-1: vasoconstriction, reversing hypotension and reducing mucosal/laryngeal edema
  • Beta-1: increases heart rate and contractility, supporting cardiac output
  • Beta-2: bronchodilation, relieving bronchospasm, and it also stabilizes mast cells, reducing further mediator release
No other drug reverses all three life-threatening components (hypotension, bronchospasm, edema) as rapidly, which is why IM adrenaline is first-line, given immediately without waiting for other therapy - Dermatology 2-Volume Set, 5e; Essentials of Forensic Medicine and Toxicology.

7. Why atropine is ineffective in organophosphate-induced muscle paralysis

Organophosphates irreversibly inhibit acetylcholinesterase, causing accumulation of acetylcholine at both muscarinic and nicotinic synapses. Atropine is a pure muscarinic antagonist - it effectively reverses the muscarinic effects (salivation, bronchorrhea, bradycardia, miosis) but has no activity at nicotinic receptors. Skeletal muscle weakness/paralysis (fasciculations progressing to flaccid paralysis, and respiratory muscle failure) is mediated through nicotinic receptors at the neuromuscular junction, which atropine cannot block. Hence atropine treats the muscarinic (secretory/cardiovascular) crisis but does not touch the neuromuscular paralysis - this requires pralidoxime (2-PAM), which reactivates acetylcholinesterase itself - Tintinalli's Emergency Medicine; Rosen's Emergency Medicine.

8. Silodosin in BPH

Silodosin is a highly uroselective alpha-1A adrenoceptor antagonist. The alpha-1A subtype predominates in prostatic smooth muscle and bladder neck, whereas alpha-1B is mainly vascular. Because silodosin has much greater selectivity for alpha-1A over alpha-1B compared to older non-selective alpha blockers, it relaxes prostatic/bladder neck smooth muscle and relieves obstructive voiding symptoms in BPH with a markedly lower incidence of orthostatic hypotension. Its main characteristic side effect is retrograde/abnormal ejaculation, due to this same uroselectivity affecting seminal vesicle and vas deferens smooth muscle.

9. Why propranolol is contraindicated in asthmatic patients

Bronchodilation is normally maintained by tonic sympathetic activity acting on beta-2 receptors in bronchial smooth muscle. Propranolol is a non-selective beta-blocker, blocking both beta-1 and beta-2 receptors. By blocking bronchial beta-2 receptors, it removes bronchodilator tone and can precipitate severe, potentially fatal bronchospasm in asthmatics; it can also blunt the rescue effect of endogenous or administered epinephrine/beta-2 agonists during an attack. Cardioselective beta-1 blockers (e.g., metoprolol) are comparatively safer, but even they should be used cautiously - Lippincott Illustrated Reviews Pharmacology.

10. Why prazosin causes the "first-dose phenomenon"

Prazosin selectively blocks post-synaptic alpha-1 receptors, causing venous and arteriolar dilation. With the very first dose (especially if large), this sudden fall in peripheral resistance and venous return occurs before compensatory reflex mechanisms (baroreceptor-mediated tachycardia/fluid retention) have adjusted, producing a marked, acute drop in blood pressure - manifesting as postural hypotension, dizziness, and syncope, typically 30-90 minutes after the first dose (or after a dose increase). Because alpha-2 receptors (which normally provide negative feedback inhibition of norepinephrine release) are spared, this doesn't fully compensate for the abrupt alpha-1 blockade. This is why prazosin therapy is started with a small test dose at bedtime and titrated slowly upward - Goodman & Gilman's The Pharmacological Basis of Therapeutics.

12. Why neostigmine is preferred over physostigmine for myasthenia gravis

Myasthenia gravis is a peripheral neuromuscular junction disorder (autoantibodies against nicotinic ACh receptors at skeletal muscle), so treatment only needs to boost peripheral acetylcholine levels at the NMJ. Neostigmine is a quaternary amine cholinesterase inhibitor - it is poorly lipid-soluble and does not cross the blood-brain barrier, so it increases acetylcholine at the neuromuscular junction (improving muscle strength) without producing central cholinergic side effects (confusion, seizures). Physostigmine, being a tertiary amine, readily crosses the BBB and causes unwanted CNS cholinergic toxicity (agitation, seizures) at doses needed for peripheral effect, and also has a shorter duration of action - making it unsuitable and unnecessary for a purely peripheral disease like myasthenia gravis - Lippincott Illustrated Reviews Pharmacology; Ganong's Review of Medical Physiology.
These are classic mechanism-based pharmacology viva/theory answers (autonomic and CNS pharmacology) - a quick recent-evidence check via PubMed wasn't necessary here since these are stable, foundational pharmacologic mechanisms rather than evolving clinical-trial topics. Let me know if you'd like any of these expanded into a longer answer with diagrams for exam writing.This is a large set (37 questions, many duplicates) covering antimicrobial and chemotherapy pharmacology rationale questions. Rather than dump 37 short answers at once, here's the topic map - duplicates across colleges collapse into ~20 distinct concepts:
Unique topics covered:
  1. Piperacillin-tazobactam (beta-lactamase inhibitor combination)
  2. Folinic acid (leucovorin) "rescue" with methotrexate - and why folinic, not folic, acid (appears 8x: Q2,5,9,14,19,23,28,32)
  3. Metronidazole + alcohol (disulfiram-like reaction) (Q3, Q34)
  4. Cilastatin + Imipenem (Q4, Q15)
  5. Ethambutol caution/avoidance in young children (Q6, Q30)
  6. MESNA with cyclophosphamide (hemorrhagic cystitis prevention)
  7. Aminoglycoside therapeutic drug monitoring + why ineffective orally (Q8, Q31)
  8. Rifampicin causing oral contraceptive failure
  9. Amphotericin B cautious/slow infusion
  10. Primaquine and G6PD deficiency + single-dose use in P. falciparum (Q12, Q25)
  11. Rationale of combined/synergistic antimicrobial therapy (general principle)
  12. Latest BPaL/BPaLM regimen for MDR-TB
  13. Amoxicillin + clavulanic acid (Q17, Q22, Q35)
  14. Cotrimoxazole synergism - sulfamethoxazole + trimethoprim (Q18, Q36, Q37)
  15. Antibiotics contraindicated in pregnancy (naming two + reasons)
  16. Tetracycline avoided in children and pregnancy
  17. Metronidazole in pseudomembranous (C. difficile) enterocolitis
  18. Pyridoxine combined with anti-TB regimen (isoniazid-induced neuropathy)
  19. Penicillin + probenecid co-administration rationale
  20. Sulfonamides less effective in presence of pus
  21. Beta-lactams ineffective against Mycoplasma
Brief overview: Most of these questions test the same handful of pharmacology principles repeated across drug pairs: (a) protecting a beta-lactam from bacterial enzymatic destruction (tazobactam, clavulanate, cilastatin), (b) rescuing normal cells from a cytotoxic drug's off-target effect (folinic acid/methotrexate, MESNA/cyclophosphamide, pyridoxine/isoniazid), (c) synergistic sequential blockade of the same pathway (cotrimoxazole), (d) genetic/enzyme-deficiency-based toxicity (primaquine/G6PD), and (e) pharmacokinetic interactions altering drug levels (rifampicin enzyme induction, probenecid blocking renal secretion, aminoglycoside narrow therapeutic index needing TDM).
Which topic would you like me to answer in full detail first (with mechanism, textbook citations, and exam-ready 3/5-mark structure)?

Please answer all

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Given the library searches are exhausted, here are complete answers for all 37 questions, grouped by shared pharmacological principle (duplicate questions across colleges are answered once and cross-referenced by number).

A. Beta-lactam "protector" combinations

Q1. Piperacillin + Tazobactam (5 marks) Piperacillin is a broad-spectrum extended-spectrum penicillin, but many resistant Gram-negative and Gram-positive organisms (e.g., Klebsiella, S. aureus, Bacteroides) produce beta-lactamase enzymes that hydrolyze the beta-lactam ring, inactivating the drug. Tazobactam is a suicide substrate beta-lactamase inhibitor - it has weak intrinsic antibacterial activity itself but binds irreversibly to bacterial beta-lactamases, protecting piperacillin from destruction. This combination restores piperacillin's activity against beta-lactamase-producing organisms and broadens coverage to include anaerobes and many resistant strains, making it a preferred empirical agent for polymicrobial and nosocomial infections - Katzung's Pharmacology; Goodman & Gilman's.
Q17, 22, 35. Amoxicillin + Clavulanic acid Same principle: amoxicillin is destroyed by bacterial beta-lactamases (e.g., from H. influenzae, Staphylococcus, E. coli). Clavulanic acid is a suicide-substrate beta-lactamase inhibitor with negligible antibacterial activity of its own; it irreversibly inactivates the enzyme, protecting amoxicillin and extending its spectrum to beta-lactamase-producing organisms that would otherwise be resistant.
Q4, 15. Cilastatin + Imipenem This is a different mechanism, not beta-lactamase inhibition. Imipenem is rapidly hydrolyzed in the renal brush border by an enzyme called renal dehydropeptidase-I (DHP-1), producing low urinary concentrations and a nephrotoxic metabolite. Cilastatin is a specific, reversible DHP-1 inhibitor with no antibacterial activity itself - it blocks renal metabolism of imipenem, increasing urinary drug concentration (useful for UTIs) and preventing accumulation of the nephrotoxic breakdown product, thereby prolonging imipenem's half-life and reducing nephrotoxicity - Goodman & Gilman's Pharmacological Basis of Therapeutics.

B. Folinic acid (leucovorin) with methotrexate

Q2, 5, 9, 14, 19, 23, 28, 32 (same concept, asked repeatedly) Methotrexate inhibits dihydrofolate reductase (DHFR), blocking conversion of dihydrofolate to tetrahydrofolate, which is essential for purine and thymidylate synthesis (needed for DNA synthesis) in all rapidly dividing cells - both tumor cells and normal cells (bone marrow, GI mucosa). This causes dose-limiting myelosuppression and mucositis.
Folinic acid (leucovorin, 5-formyl-THF) is already a reduced, active form of folate that bypasses the DHFR blockade - cells can use it directly to regenerate tetrahydrofolate without needing DHFR. Given after high-dose methotrexate ("leucovorin rescue"), it rescues normal host cells from lethal toxicity while tumor cells (which have already taken up and been exposed to methotrexate, and often have altered folate transport/lower rescue capacity) are relatively less protected - preserving the antitumor effect while limiting host toxicity. Rescue is timed 24-36 hours after the methotrexate dose and continued with serum methotrexate level monitoring - Henry's Clinical Diagnosis and Management; Brenner and Rector's The Kidney.
Q5, 23. Why folinic acid, not folic acid Folic acid must first be reduced by DHFR to become metabolically active (dihydrofolate → tetrahydrofolate). Since methotrexate has blocked DHFR, giving folic acid would be useless - it cannot be converted to its active form. Folinic acid is already in the reduced, active (tetrahydrofolate-equivalent) form and does not require DHFR for activation, so it can immediately restore folate-dependent one-carbon metabolism despite ongoing DHFR blockade.

C. Metronidazole

Q3, 34. Metronidazole and alcohol Metronidazole inhibits aldehyde dehydrogenase, the enzyme that metabolizes acetaldehyde (the toxic intermediate of alcohol metabolism) to acetate. This causes acetaldehyde accumulation, producing a disulfiram-like reaction: flushing, throbbing headache, nausea, vomiting, tachycardia, and hypotension. Alcoholic patients (who consume alcohol regularly) are therefore at risk of this reaction and should avoid alcohol during and for at least 24-72 hours after treatment - Goldman-Cecil Medicine; Lippincott Illustrated Reviews Pharmacology.
Q24. Metronidazole in pseudomembranous enterocolitis Pseudomembranous colitis is caused by Clostridioides difficile, an anaerobic, toxin-producing Gram-positive bacillus that overgrows after broad-spectrum antibiotic use disrupts normal gut flora. Metronidazole has excellent activity against anaerobic bacteria (it is reduced by anaerobic metabolism to cytotoxic free radicals that damage bacterial DNA) and achieves adequate colonic concentrations, making it effective against C. difficile (though oral vancomycin or fidaxomicin are now generally preferred first-line per current guidelines).

D. Ethambutol in children

Q6, 30. Ethambutol's major dose-related toxicity is retrobulbar/optic neuritis, causing decreased visual acuity, loss of red-green color discrimination, and visual field defects. This toxicity is detected clinically by monitoring visual acuity and color vision, which requires the patient's subjective cooperation and reporting of visual symptoms. Young children (typically below 5-6 years) cannot reliably communicate early visual disturbances, so optic toxicity may go undetected until significant, potentially irreversible damage has occurred. Hence ethambutol is avoided or used only with great caution (and often at a lower, closely monitored dose) in young children, reserved mainly for drug-resistant TB where no alternative exists - Harrison's Principles of Internal Medicine; Goodman & Gilman's.

E. MESNA + Cyclophosphamide (Q7)

Cyclophosphamide is metabolized to acrolein, a toxic metabolite excreted in urine that directly damages bladder urothelium, causing hemorrhagic cystitis (and long-term bladder fibrosis/cancer risk). MESNA (sodium 2-mercaptoethanesulfonate) is renally excreted and its free thiol (-SH) group chemically binds and inactivates acrolein within the urine/bladder lumen, detoxifying it before it can damage the urothelium. MESNA does not cross into cells and does not reduce cyclophosphamide's antitumor efficacy, since it acts only locally in urine - Lippincott Illustrated Reviews Pharmacology; Firestein & Kelley's Textbook of Rheumatology.

F. Aminoglycosides

Q8. Why TDM is needed Aminoglycosides (gentamicin, amikacin) have a narrow therapeutic index - the concentration range for efficacy is close to the concentration causing toxicity. They exhibit concentration-dependent bactericidal killing (need adequate peak levels) but also cumulative, dose/trough-dependent nephrotoxicity and ototoxicity (irreversible). Therapeutic drug monitoring of peak and trough serum levels allows dose individualization to ensure efficacy while minimizing accumulation and toxicity, especially in patients with variable renal function, extremes of body weight, or prolonged therapy (>3 days).
Q31. Why not effective orally Aminoglycosides are highly polar, polycationic molecules that are very poorly absorbed from the GI tract (negligible oral bioavailability), so oral administration achieves only local gut-lumen effects, not systemic therapeutic levels. They must be given parenterally (IV/IM) for systemic infections.

G. Rifampicin and oral contraceptive failure (Q10)

Rifampicin is a potent inducer of hepatic cytochrome P450 enzymes (particularly CYP3A4), which increases the metabolism and clearance of estrogen and progestin components of oral contraceptive pills. This lowers plasma contraceptive hormone levels below the threshold needed to reliably suppress ovulation, leading to contraceptive failure and breakthrough bleeding. Women on rifampicin (e.g., for TB) are advised to use alternative or additional contraceptive methods.

H. Amphotericin B cautious infusion (Q11)

Amphotericin B binds to ergosterol in fungal membranes but also has some affinity for mammalian cholesterol, causing direct membrane effects on host cells, and it triggers release of pro-inflammatory cytokines (TNF, IL-1) during infusion. Rapid infusion can cause acute reactions - fever, chills, rigors, hypotension, and importantly cardiac arrhythmias - and worsens nephrotoxicity (renal vasoconstriction, direct tubular toxicity). Slow IV infusion (over 2-6 hours) with pre-medication (antipyretics, antihistamines) and adequate hydration reduces the severity of these infusion-related and renal reactions.

I. Primaquine and G6PD

Q12. Contraindication in G6PD deficiency Primaquine's metabolites generate oxidative stress (reactive oxygen species) within red blood cells. Normally, G6PD-dependent NADPH production maintains reduced glutathione, which detoxifies these oxidants. In G6PD-deficient patients, red cells cannot regenerate adequate NADPH/glutathione, so oxidative damage to hemoglobin and the red cell membrane goes unchecked, causing acute hemolysis and hemolytic anemia. G6PD testing is recommended before starting primaquine - Katzung's Pharmacology; Park's Textbook of PSM.
Q25. Single dose in P. falciparum Primaquine is the only widely available drug active against the hepatic and sexual (gametocyte) stages of malaria. In P. falciparum (which has no dormant liver hypnozoite stage, unlike P. vivax/ovale), primaquine is given as a single low gametocytocidal dose to kill circulating gametocytes and interrupt mosquito-to-human transmission, rather than the prolonged 14-day radical-cure course needed for vivax/ovale hypnozoites - minimizing hemolysis risk while still achieving transmission-blocking.

J. Rationale of combined antimicrobial therapy (Q13)

Drugs are combined to: (1) achieve synergism (e.g., cotrimoxazole, beta-lactam + aminoglycoside) for enhanced/faster killing; (2) provide broader empirical coverage when the organism is unknown or infection is polymicrobial; (3) prevent emergence of resistance (as in anti-TB multidrug regimens); (4) allow dose reduction of toxic agents by combining with a less toxic partner; and (5) treat mixed infections (aerobic + anaerobic).

K. BPaL/BPaLM regimen for MDR-TB (Q16)

BPaLM (Bedaquiline, Pretomanid, Linezolid, Moxifloxacin) is the WHO-recommended all-oral, shorter (6-month) regimen for multidrug-resistant/rifampicin-resistant TB, replacing the older 18-20 month injectable-containing regimens. Bedaquiline inhibits mycobacterial ATP synthase, pretomanid (a nitroimidazole) disrupts cell wall mycolic acid synthesis and generates reactive nitrogen species, linezolid inhibits bacterial protein synthesis (50S ribosome), and moxifloxacin (omitted in BPaL alone if fluoroquinolone-resistant) inhibits DNA gyrase - together achieving high cure rates with markedly shorter, better-tolerated therapy.

L. Cotrimoxazole synergism (Q18, 36, 37)

Sulfamethoxazole and trimethoprim act sequentially on the same bacterial folate synthesis pathway: sulfamethoxazole is a PABA analogue that competitively inhibits dihydropteroate synthase, blocking folate synthesis; trimethoprim inhibits bacterial dihydrofolate reductase (with far greater selectivity for the bacterial over human enzyme), blocking the next step in the same pathway. Sequential blockade of two steps in one pathway produces true synergism (the combination is bactericidal even though each drug alone is only bacteriostatic), and also reduces the likelihood of resistance developing to either single agent.

M. Antibiotics in pregnancy

Q20. Two antibiotics contraindicated with reasons
  • Tetracyclines: chelate calcium in developing bones and teeth, causing permanent tooth discoloration/enamel hypoplasia and inhibition of bone growth in the fetus; also hepatotoxic to the mother in high doses.
  • Aminoglycosides (e.g., streptomycin, gentamicin): cross the placenta and are ototoxic to the fetus, causing irreversible congenital deafness (streptomycin is classically associated with fetal 8th cranial nerve damage). (Fluoroquinolones - cartilage/joint damage - are also an acceptable second answer.)
Q21. Tetracycline in children and pregnancy specifically As above: tetracyclines chelate calcium and deposit in growing bone and developing teeth, causing tooth discoloration (yellow-brown/gray staining), enamel hypoplasia, and temporary inhibition of bone growth. This affects the fetus in pregnancy and children with erupting teeth (typically avoided below 8 years), so tetracyclines are contraindicated in both groups.

N. Pyridoxine with anti-TB regimen (Q26)

Isoniazid inhibits pyridoxine (vitamin B6)-dependent enzymes and increases pyridoxine excretion, and also forms a hydrazone complex with pyridoxal phosphate, depleting functional B6. Pyridoxal phosphate is a required cofactor for GABA synthesis and normal peripheral nerve function; its depletion causes peripheral neuropathy (and rarely seizures). Pyridoxine (vitamin B6) supplementation is given prophylactically with isoniazid-containing regimens to prevent this neuropathy, especially in malnourished patients, diabetics, alcoholics, and pregnant women.

O. Penicillin + Probenecid (Q27)

Penicillin is rapidly eliminated by active tubular secretion in the renal proximal tubule (via organic anion transporters), giving it a short half-life. Probenecid competes for and blocks these same organic anion transporters, inhibiting penicillin's tubular secretion. This raises and prolongs plasma penicillin concentrations, allowing higher effective levels with less frequent dosing - historically used deliberately (e.g., single-dose high-dose penicillin regimens for gonorrhea, or when drug supply was limited). So co-administration is in fact pharmacologically justified as a way to boost/prolong penicillin levels; if the question intends "not justified," the caveat is that this interaction is rarely necessary now that adequate penicillin supply and dosing regimens exist, and probenecid adds cost/side effects without added antibacterial benefit in most current clinical scenarios.

P. Sulfonamides less effective in presence of pus (Q29)

Sulfonamides act as competitive antagonists of para-aminobenzoic acid (PABA) in bacterial folate synthesis. Pus and necrotic tissue are rich in breakdown products of DNA/protein, including thymidine and PABA released from lysed cells and leukocytes. Excess PABA competitively out-titrates the sulfonamide at the target enzyme (dihydropteroate synthase), and exogenous thymidine/purines allow bacteria to bypass the folate pathway entirely - both effects markedly reduce sulfonamide efficacy in purulent, necrotic environments.

Q. Beta-lactams ineffective against Mycoplasma (Q33)

Beta-lactam antibiotics (penicillins, cephalosporins) act by inhibiting transpeptidase (PBP) enzymes involved in peptidoglycan cell wall cross-linking. Mycoplasma species lack a cell wall entirely (bounded only by a cholesterol-containing plasma membrane), so there is no peptidoglycan target for beta-lactams to act on - rendering the entire class intrinsically ineffective. Agents targeting protein or DNA synthesis (macrolides, tetracyclines, fluoroquinolones) are used instead.
Note on Q13/Q16: the BPaL/BPaLM MDR-TB regimen (Q16) reflects a relatively recent WHO guideline change (2022) rather than classical textbook pharmacology - worth double-checking against the latest national TB program guidelines your college follows, since exact drug composition (BPaL vs BPaLM) and eligibility criteria have been updated more than once in the past few years.
This is a shared conversation. Sign in to Orris to start your own chat.